TCGA-A8-A096-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.550
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.550
- IL6_JAK_STAT3_SIGNALING+0.500
- INFLAMMATORY_RESPONSE+0.480
- UV_RESPONSE_DN+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- TNFA_SIGNALING_VIA_NFKB+0.430
- COMPLEMENT+0.410
- APOPTOSIS+0.370
Top 10 suppressed
- MYC_TARGETS_V2-0.520
- MYC_TARGETS_V1-0.380
- OXIDATIVE_PHOSPHORYLATION-0.380
- E2F_TARGETS-0.270
- KRAS_SIGNALING_DN-0.240
- UNFOLDED_PROTEIN_RESPONSE-0.230
- DNA_REPAIR-0.220
- PANCREAS_BETA_CELLS-0.180
- ADIPOGENESIS-0.160
- G2M_CHECKPOINT-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-6712-01A-11R-1858-07 | — | cohortA1 | 0.931 |
| 2 | 9f621704-2ece-4b25-be28-5fe14f71048d | — | — | 0.929 |
| 3 | TCGA-63-A5MN-01A-22R-A27Q-07 | — | cohortA1 | 0.929 |
| 4 | TCGA-A8-A0A1-01A-11R-A00Z-07 | — | A | 0.913 |
| 5 | MDT-AP-0390 | Med | Medulloblastoma | 0.908 |
| 6 | MDT-AP-2029 | Med | Medulloblastoma | 0.904 |
| 7 | TCGA-E2-A1B1-01A-21R-A12P-07 | — | A | 0.899 |
| 8 | TCGA-69-7761-01A-11R-2170-07 | — | cohortA1 | 0.898 |
| 9 | MDT-AP-3277 | Med | Medulloblastoma | 0.896 |
| 10 | TCGA-69-7978-01A-11R-2187-07 | — | cohortA1 | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |